Arvinas Lands First FDA Approval for PROTAC Therapy, VEPPANU
Event summary
- Arvinas and Pfizer received FDA approval for VEPPANU (vepdegestrant), a PROTAC therapy, for ESR1-mutated, ER+/HER2- advanced breast cancer.
- The approval was granted ahead of the previously assigned PDUFA date of June 5, 2026.
- VEPPANU demonstrated a 43% reduction in the risk of disease progression or death compared to fulvestrant in the VERITAC-2 trial.
- Arvinas and Pfizer plan to select a third-party commercialization partner.
The big picture
The FDA approval of VEPPANU represents a significant validation of the PROTAC protein degradation technology, which has been in development for nearly two decades. This marks a potential paradigm shift in drug development, moving beyond traditional small molecules to targeted protein removal. While the initial market for ESR1-mutated breast cancer is relatively niche, the broader implications for treating previously ‘undruggable’ targets could be substantial, attracting further investment and competition in the biotechnology sector.
What we're watching
- Commercialization
- The selection and performance of the third-party commercialization partner will be critical to VEPPANU’s market penetration and revenue generation, given Pfizer’s stated intention to outsource distribution.
- Competitive Landscape
- The emergence of VEPPANU as the first PROTAC therapy will likely accelerate investment and development in this novel therapeutic modality, potentially leading to increased competition in the oncology space.
- Clinical Expansion
- The success of VEPPANU in ESR1-mutated breast cancer will influence Arvinas’ strategy for expanding its PROTAC pipeline to other oncology and non-oncology indications.